You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


ICEBERG study demonstrates improved outcomes of nasal spray for TRD

Janssen’s ICEBERG study has demonstrated that esketamine nasal spray (NS) has shown improved outcomes in an indirect treatment comparison with other real-world treatments for treatment-resistant depression (TRD).